S-adenosyl L-methionine in CNS diseases;S-adenozylo L-metionina w schorzeniach OUN

Psychiatria Polska

Volumn 45, Issue 6, 2011, Pages 923-931

  Krzystanek, Marek ^a   Pałasz, Artur ^b   Krzystanek, Ewa ^c   Krupka Matuszczyk, Irena ^a   Wiaderkiewicz, Ryszard ^b   Skowronek, Rafał ^b  

^a Katedra i Klinika Psychiatrii i Psychoterapii   (Poland)

^b NONE   (Poland)

^c Katedra i Klinika Neurologii   (Poland)

Author keywords

Complementary medicine; One carbon metabolism; S adenosylmethionine

Indexed keywords

ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT; S ADENOSYLMETHIONINE;

AGGRESSIVENESS; ALCOHOL LIVER DISEASE; CANCER RISK; CENTRAL NERVOUS SYSTEM DISEASE; COGNITIVE DEFECT; DEMENTIA; DEPRESSION; DIET SUPPLEMENTATION; HUMAN; JOINT FUNCTION; LIVER CIRRHOSIS; LIVER PROTECTION; MONOTHERAPY; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; DEPRESSIVE DISORDER; DIETARY SUPPLEMENTS; HUMANS; MENTAL DISORDERS; S-ADENOSYLMETHIONINE; SCHIZOPHRENIA;

EID: 84055199099     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Cederbaum AI. Hepatoprotective effects of S-adenosyl-L-methionine against alcohol- and cytochrome P450 2E1-induced liver injury. World J. Gastroenterol. 2010; 16 (11): 1366-1376.
2. Lee ES, Chen H, Hardman C, Simm A, Charlton C. Excessive S-adenosyl-L-methionine-dependent methylation increases levels of methanol, formaldehyde and formic acid in rat brain striatal homogenates: possible role in S-adenosyl-L-methionine-induced Parkinson's disease-like disorders. Life Sc. 2008; 83 (25-26): 821-827.
3. Mischoulon D, Fava M. Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. Am. J. Clin. Nutr. 2002 (supl.); 76: 1158-1161.
4. Miller AL. The methylation, neurotransmitter, and antioxidant connections between folate and depression. Altern. Med. Rev. 2008; 13 (3): 216-226.
5. Lee DH, Jacobs DR Jr, Porta M. Hypothesis: a unifying mechanism for nutrition and chemicals as lifelong modulators of DNA hypomethylation. Environ. Health Perspect. 2009; 117 (12): 1799-1802.
6. Loenen WA. S-adenosylmethionine: jack of all trades and master of everything? Biochem. Soc. Trans. 2006; 34 (2): 330-333.
7. Akbarian S, Huang HS. Epigenetic regulation in human brain - focus on histone lysine methylation. Biol. Psychiatry 2009; 65 (3): 198-203.
8. Yang L, Xia L, Wu DY, Wang H, Chamsky HA, Schubach WH, Hickstein DD, Zhang Y. Molecular cloning of ESET, a novel histone H3-specific methyltransferase that interacts with ERG transcription factor. Oncogene 2002; 21 (1): 148-152. (Pubitemid 34076387)
9. Ryu H, Lee J, Hagerty SW, Soh BY, McAlpin SE, Cormier KA, Smith KM, Ferrante RJ. ESET/SETDB1 gene expression and histone H3(K9) trimethylation on Huntington's disease. Proc. Nat. Acad. Sc. USA 2006; 103 (50): 19176-19181. (Pubitemid 350002846)
10. Kleefstra T, Brunner HG, Amiel J, Oudakker AR, Nillesen WM, Magee A, Genevieve D, Cormier-Daire V, van Esch H, Fryns JP, Hamel BC, Sistermans EA, de Vries BB, van Bokhoven M. Loss of function mutations in euchromatin histone methyl transferase (EHMT1) cause the 9q34 subtelomeric deletion syndrome. Am. J. Hum. Genet. 2006; 79 (2): 370-377. (Pubitemid 44141836)
11. Iwase S, Lan F, Bayliss P, de la Torre-Ubieta L, Huarte M, Qi HH, Whetstine JR, Bonni A, Roberts TM, Shi Y. The X-linked mental retardation gene SMCX/JARD1C defines a family of histone H3 lysine 4 demethylases. Cell 2007; 128 (6): 1077-1088. (Pubitemid 46437259)
12. Wynder C, Hakimi MA, Epstein JA, Shilatifard A, Shiekhattar R. Recruitment of MLL by HMG domain protein iBRAF promotes neural difrerentiation. Nat. Cell Biol. 2005; 7 (11): 1113-1117.
13. Kim SY, Levenson JM, Korsmeyer S, Sweatt JD, Schumacher A. Developmental regulation of Eed complex composition governs a switch in global histone modification in brain. J. Biol. Chem. 2007; 282 (13): 9962-9972. (Pubitemid 47104642)
14. Huang HS, Matevossian A, Whittle C, Kim SY, Schumacher A, Baker SP. Akbarian S. Prefrontal dysfunction in schizophrenia involves mixed-lineage leukemia 1-regulated histone methylation at GABAergic gene promoters. J. Neurosc. 2007; 27 (42): 11254-11262. (Pubitemid 47621326)
15. Huang HS, Akbarian S. GAD1 mRNA expression and DNA methylation in prefrontal cortex of subjects with schizophrenia. PLoS ONE 2007; 2 (8): 809.
16. Wilson AS, Power BE, Molloy PL. DNA hypomethylation and human diseases. Biochim. Biophys. Acta 2007; 1775 (1): 138-162. (Pubitemid 44881198)
17. Zaina S, Lindholm MW, Lund G. Nutrition and aberrant DNA methylation patterns in atherosclerosis: more than just hyperhomocysteinemia? J. Nutr. 2005; 135 (1): 5-8. (Pubitemid 40094312)
18. Davis CD, Uthus EO. DNA methylation, cancer susceptibility, and nutrient interactions. Exp. Biol. Med. (Maywood) 2004; 229 (10): 988-995. (Pubitemid 39431078)
19. Świȩcicki L, Rosnowska E. Poziomy kwasu foliowego i witaminy B12 w surowicy krwi pacjentów hospitalizowanych z choroba̧ psychiczna̧ (przegla̧d piśmiennictwa i badanie pilotowe). Psychiatr. Pol. 1992; 26 (5): 399-409.
20. Gören JL, Stoll AL, Damico KE, Sarmiento IA, Cohen BM. Bioavailability and lack of toxicity of S-adenosyl-L-methionine (SAMe) in humans. Pharmacother. 2004; 24 (11): 1501-1507. (Pubitemid 39426345)
21. Strous RD, Ritsner MS, Adler S, Ratner Y, Maayan R, Kotler M, Lachman H, Weizman A. Improvement of aggressive behavior and quality of life impairment following S-adenosyl-methionine (SAM-e) augmentation in schizophrenia. Eur. Neuropsychopharmacol. 2009; 19 (1): 14-22.
22. Deligiannidis KM, Freeman MP. Complementary and alternative medicine for the treatment of depressive disorders in women. Psychiatr. Clin. North Am. 2010; 33 (2): 441-463.
23. Mischoulon D. Update and critique of natural remedies as antidepressant treatments. Obstet. Gynecol. Clin. North Am. 2009; 36 (4): 789-807.
24. Carney MW, Sheffield BF. Serum folic acid and B12 in 272 psychiatric in-patients. Psychol. Med. 1978; 8: 139-144. (Pubitemid 8266872)
25. Gilbody S, Lightfoot T, Sheldon T. Is low folate a risk factor for depression? A meta-analysis and exploration of heterogeneity. J. Epidemiol. Comm. Health 2007; 61: 631-637. (Pubitemid 46998897)
26. Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J. Affect. Disord. 2000; 60: 121-130.
27. Alpert JE, Mischoulon D, Rubenstein GE, Bottonari K, Nierenberg AA, Fava M. Folinic acid (Leucovorin) as an adjunctive treatment for SSRI-refractory depression. Ann. Clin. Psychiatry 2002; 14: 33-38. (Pubitemid 34538830)
28. Papakostas GI. Evidence for S-adenosyl-L-methionine (SAM-e) for the treatment of major depressive disorder. J. Clin. Psychiatry 2009 (supl. 5); 70: 18-22.
29. Pancheri P, Scapicchio P, Chiaie RD. A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L- methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. Int. J. Neuropsychopharmacol. 2002; 5 (4): 287-294. (Pubitemid 35470348)
30. Delle Chiaie R, Pancheri P, Scapicchio P. Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. Am. J. Clin. Nutr. 2002; 76 (5): 1172-1176.
31. Spillmann M, Fava M. S-adenosyl-methionine (ademethionine) in psychiatric disorders. CNS Drugs 1996; 6: 416-425.
32. Papakostas GI, Alpert JE, Fava M. S-adenosyl-methionine in depression: a comprehensive review of the literature. Curr. Psychiatry Rep. 2003; 5 (6): 460-466. (Pubitemid 38899242)
33. Salmaggi P, Bressa GM, Nicchia G, Coniglio M, La Greca P, Le Grazie C. Double-blind, placebo-controlled study of S-adenosyl-L-methionine in depressed postmenopausal women. Psychother. Psychosom. 1993; 59 (1): 34-40. (Pubitemid 23082150)
34. Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava M. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am. J. Psychiatry 2010; 167 (8): 942-948.
35. Scarpa S, Cavallaro RA, D'Anselmi F, Fuso A. Gene silencing through methylation: an epigenetic intervention on Alzheimer disease. J. Alzheimers Dis. 2006; 9 (4): 407-414. (Pubitemid 44253355)
36. Morrison LD, Smith DD, Kish SJ. Brain S-adenosylmethionine levels are severely decreased in Alzheimer's disease. Neurochem. 1996; 67 (3): 1328-1331. (Pubitemid 26277949)
37. Bottiglieri T, Hyland K. S-adenosylmethionine levels in psychiatric and neurological disorders: a review. Acta Neurol. Scand. 1994 (supl.); 154: 19-26.
38. Panza F, Frisardi V, Capurso C, D'Introno A, Colacicco AM, Di Palo A, Imbimbo BP, Vendemiale G, Capurso A, Solfrizzi V. Polyunsaturated fatty acid and S-adenosylmethionine supplementation in predementia syndromes and Alzheimer's disease: a review. Scient. World J. 2009; 9: 373-389.
39. Avila MA, García-Trevijano ER, Martínez-Chantar ML, Latasa MU, Pérez-Mato I, Martínez-Cruz LA, del Pino MM, Corrales FJ, Mato JM. S-Adenosylmethionine revisited: its essential role in the regulation of liver function. Alcohol 2002; 27: 163-167. (Pubitemid 34876917)
40. Lu SC, Ramani K, Ou X, Lin M, Yu V, Ko K, Park R, Bottiglieri T, Tsukamoto H, Kanel G, French SW, Mato JM, Moats R, Grant E. S-adenosylmethionine in the chemoprevention and treatment of hepatocellular carcinoma in a rat model. Hepatol. 2009; 50 (2): 462-471.
41. Rutjes AW, Nüesch E, Reichenbach S, Jüni P. S-Adenosylmethionine for osteoarthritis of the knee or hip. Cochrane Database Syst. Rev. 2009; (4): CD007321.